Eligible patients had unresectable locally advanced or limited metastatic disease (single-site metastases). They had at least one measurable lesion, an Eastern Cooperative Oncology Group ...

The FDA granted fast track status to IBI363 for the treatment of patients with advanced squamous lung cancer after prior ...

The Food and Drug Administration (FDA) has granted Priority Review to the New Drug Application for zongertinib for the treatment of adult patients with ...

Among patients in the real world with unresectable or metastatic urothelial carcinoma, Padcev significantly improved overall ...

Findings showed datopotamab deruxtecan reduced the risk of disease progression or death by 37% compared with chemotherapy.

Ridgefield, Conn., U.S., and Ingelheim, GermanyZongertinib would be the first orally administered, targeted therapy for previously treated ...

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for belzutifan for the treatment of adult and pediatric patients aged 12 years and ...

Third-line enfortumab vedotin improved outcomes in metastatic urothelial carcinoma, per real-world data from the EV-301 trial ...

“LAPIS is an important study for the future of locally advanced pancreatic ... agents that are able to convert unresectable to potentially resectable disease followed by preventing recurrence ...

"The CARES-oo5 study showed a clinically meaningful and statistically significant improvement in the primary endpoint of PFS for unresectable ... response (ORR) and disease control (DCR) rates ...